Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society

• Main Authors: Rajadurai, Pathmanathan, Cheah, Phaik Leng, How, Soon Hin, Liam, Chong Kin, Ahmad Annuar, Muhammad Azrif, Omar, Norhayati, Othman, Noriah, Mohd Marzuki, Nurhayati, Pang, Yong Kek, Ahmad Bustamam, Ros Suzanna, Tho, Lye Mun
• Format: Article
• Language: English; English
• Published: Elsevier Ireland Ltd 2019
• Subjects: RC Internal medicine; RC667 Specialties of Internal Medicine-Diseases of Circulatory (Cardiovascular) System
• Online Access: http://irep.iium.edu.my/79720/1/79720_Molecular%20testing%20for%20advanced%20non-small.pdf; http://irep.iium.edu.my/79720/2/79720_Molecular%20testing%20for%20advanced%20non-small_SCOPUS.pdf; http://irep.iium.edu.my/79720/; https://www.sciencedirect.com/science/article/pii/S016950021930580X

In the recent years, increased understanding of the molecular profiles of non-small cell lung cancer (NSCLC) has allowed for targeted treatment of actionable genetic mutations. The management of NSCLC now requires multiple molecular tests to guide the treatment strategy. In the light of this, there is a need to establish a molecular testing consensus statement for advanced NSCLC patients in Malaysia. This Malaysian consensus statement was developed by a panel of experts, chaired by a pathologist and composed of three other pathologists, four respiratory physicians and three oncologists. It reflects currently available scientific data and adaptations of recommendations from international guidelines to the local landscape. Expert recommendations on different aspects of molecular testing agreed upon by the panel are provided as structured discussions. These recommendations address the appropriate patients and samples to be tested, as well as when and how these tests should be performed. The algorithms for molecular testing in metastatic NSCLC, in the first line setting and upon disease progression beyond first line therapy, were developed.